Less Ads, More Data, More Tools Register for FREE

TechMARK movers: AstraZeneca drops SkyePharma product

Mon, 07th Mar 2011 12:04
Shares in drug discovery company SkyePharma have slumped following news that AstraZeneca has decided to stop production of one of its drugs using SkyePharma's drug delivery technology. There were manufacturing problems because of technical aspects of the PULMICORT (budesonide) 100 and 200 µg/dose HFA pMDI (pressurised metered dose inhaler). Any product already made will be sold. SkyePharma says that it earned a "mid-teens royalty" on the product and they accounted for 5% of SkyePharma's revenues. Total revenues were £55.9m in 2009 and were slightly higher in 2010. Revenues and profits slumped at telecommunications and healthcare equipment supplier BATM in 2010 after it was hit by lower sales to telecoms services giant Nokia Siemens Networks. Pre-tax profits slumped from $18.5m to $1.03m on revenues that were down to $120.6m, from $135.4m. However, BATM says that sales have recovered and are expected to continue doing so.Translation software provider SDL reported an 18% increase in revenues to £203.5m in 2010. Pre-exceptionals profit was 19% ahead at £35.4m. SDL expects 2011 to be another good year for the business. There is £46.6m in the bank and a maiden final dividend of 5.5p a share is proposed. FTSE TechMARK - Risers Imagination Technologies Group (IMG) 469.60p +3.85%SDL (SDL) 657.00p +3.71%XP Power Ltd. (DI) (XPP) 1,869.00p +3.55%Aveva Group (AVV) 1,707.00p +3.14%ARM Holdings (ARM) 598.50p +2.57%Telecity Group (TCY) 493.10p +2.52%Dialight (DIA) 755.00p +2.51%Kewill (KWL) 95.00p +1.47%Parity Group (PTY) 23.50p +1.08%NCC Group (NCC) 577.50p +0.87%FTSE TechMARK - Fallers Skyepharma (SKP) 35.00p -16.67%BATM Advanced Communications Ltd. (BVC) 22.75p -11.65%Oxford Biomedica (OXB) 6.15p -7.45%Vectura Group (VEC) 63.00p -4.55%Alterian (ALN) 176.00p -3.43%Ricardo (RCDO) 381.25p -2.24%Antisoma (ASM) 2.65p -1.85%Consort Medical (CSRT) 546.00p -1.80%Renishaw (RSW) 1,668.00p -1.59%COLT Group SA (COLT) 148.40p -1.13% Astrazeneca Batm Advanced

Shares in this article

Related News

AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial
9 hours ago

AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial

* AstraZeneca advancing obesity strategy with experimental pill

AstraZeneca hails phase 3 trial results of inhibitor Ultomiris
1 day ago

AstraZeneca hails phase 3 trial results of inhibitor Ultomiris

(Alliance News) - AstraZeneca PLC on Saturday announced new data on its kidney disease treatment Ultomiris.

PRESS: AstraZeneca warns it could delay Europe drug launches - FT
2 days ago

PRESS: AstraZeneca warns it could delay Europe drug launches - FT

(Alliance News) - AstraZeneca PLC could be forced to withhold new medicines from the UK and Europe unless governments pay more for innovative drugs, C...